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Post-crizotinib management of effective
ceritinib therapy in a patient with ALK-
positive non-small cell lung cancer
Brian Won1, Isa Mambetsariev2 and Ravi Salgia2*
Abstract
Background: We report the re-biopsied diagnosis of a patient with anaplastic lymphoma receptor tyrosine kinase
(ALK)-positive lung adenocarcinoma successfully treated with ceritinib 450 mg/day taken with food following disease
progression and gastrointestinal intolerance to crizotinib.
Case presentation: A 74-year old female patient initially diagnosed with ALK-negative lung adenocarcinoma
responded to initial standard chemotherapy. The patient was subsequently re-tested by next generation sequencing
(NGS) and found to have ALK EIF2AK3-ALK fusion, and responded to crizotinib, but ultimately progressed and showed
intolerance to this ALK inhibitor. She was then successfully treated with ceritinib 450 mg/day taken with food, has not
suffered from any further gastrointestinal side-effects, and remains on ceritinib treatment after 12 months.
Conclusions: Second-line ceritinib treatment, when administered at 450 mg/day with food, is both well tolerated and
efficacious in a patient with previously treated lung adenocarcinoma who had discontinued crizotinib due to disease
progression and gastrointestinal adverse effects (AEs).
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Background
The treatment of non-small cell lung cancer (NSCLC)
has now changed dramatically in recent years and is no
longer an unspecific approach based on platinum doub-
let chemotherapy when patients are molecularly tested
and diagnosed with actionable mutations. For example,
anaplastic lymphoma receptor tyrosine kinase (ALK)
gene rearrangement occurs in around 5 % of NSCLC
cases [1], and is detected by several methods, including
fluorescence in situ hybridization (FISH), immunohisto-
chemistry (IHC), quantitative polymerase chain reaction
(qPCR), next generation sequencing (NGS), and reverse
transcription polymerase chain reaction of cDNA (RT-
PCR) [2]. Out of those methods, FISH is the gold stand-
ard in detecting ALK rearrangement in NSCLC due to
its detection of rearrangements regardless of what the
variant and fusion partner, use of archival formalin-fixed
paraffin embedded tissue, low tumor cell requirement
(~100 tumor cells), clinical validation, and its FDA ap-
proval for clinical applications [2]. However, FISH is
costly, does not identify specific rearrangements, may
miss rare rearrangements, and requires specialized train-
ing [2]. Next-generation sequencing (NGS) is another
method in detecting ALK rearrangements and refers to a
variety of platforms that parallel sequences multiple ana-
lytes simultaneously; NGS has a relatively quick turn-
around, low cost, and high coverage [3]. In one case, Ali
et al. identified 31 ALK positive patients who had both
NGS and FISH testing done [4]. Out of those 31 pa-
tients, 11 (35 %) were previously ALK FISH negative, in-
dicating that NGS holds value in ALK testing in
comparison with FISH [4]. Crizotinib (Xalkori®) is ap-
proved as first-line treatment when ALK-rearrangement
as detected by FISH [5]. However, despite initial re-
sponse rates of 60 % and a median PFS of 8–10 months
[1, 6], patients tend to relapse after 1–2 years, often lim-
iting its long-term use [7, 8]. This relapse is often due to
developed resistance to crizotinib where in approximately
30 % of resistance cases, patients’ tumors have developed
secondary mutations within the kinase domain of ALK [7,
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9, 10]. Common resistance mutations include gatekeeper
L1196M, G1269A, and G1202R mutations [11]. Other
mechanisms of crizotinib resistance are due to amplifica-
tion of the ALK fusion gene, which can occur alone or in
combination with secondary resistance mutations [8, 9].
Last, mechanisms of resistance have been attributed to al-
ternative or bypass signaling pathways, such as the epider-
mal growth factor receptor (EGFR) and insulin-like
growth factor-1 (IGF1R) pathways [7, 10]. Ceritinib (Zyka-
diaTM) is a once daily oral, small-molecule, adenosine tri-
phosphate (ATP)-competitive ALK inhibitor that is 20
times more potent against ALK than crizotinib in preclin-
ical studies, with activity against common secondary ALK
mutations that confer resistance to crizotinib [12]. Ceriti-
nib was granted accelerated approval by the US FDA in
2014 for treating metastatic, ALK-positive NSCLC that
has progressed on or is intolerant to crizotinib, based
on response rate and duration of response [13]. Ceriti-
nib is currently recommended at a dose of 750 mg/day,
administered orally on an empty stomach (not within
2 h of a meal) [13]. In a Phase I study in ALK inhibitor-
treated and -naïve patients with NSCLC, overall re-
sponse rates (ORRs) of 56 % and 72 % respectively,
were achieved, with a median duration of response of
9.7 months. Median progression free survival (PFS) was
6.9 months in prior ALK inhibitor-treated patients and
18.4 months in ALK inhibitor-naïve patients [14]. In
this case report, we present a female patient initially di-
agnosed with ALK-negative lung adenocarcinoma that
responded to standard chemotherapy, but was subse-
quently re-tested by NGS and found to be ALK-posi-
tive. The patient responded to crizotinib but ultimately
progressed and showed gastrointestinal intolerance to
the drug. She has been treated successfully with ceriti-
nib 450 mg/day taken with food and remains on ceriti-
nib treatment after 12 months.
Case presentation
A 74 year-old Caucasian female never-smoker initially
presented with a pleural effusion and was diagnosed
with invasive adenocarcinoma following a pleural biopsy.
The pleural biopsy performed revealed dense fibrous tis-
sue with invasive adenocarcinoma with mucin produc-
tion and associated psammomatous calcifications. The
patient was initially treated with carboplatin, paclitaxel,
and bevacizumab with good response, and she continued
on maintenance bevacizumab for four years after diag-
nosis. Subsequently treatment was switched to peme-
trexed but had to be stopped due to secondary fatigue
and failure to thrive. Molecular (EGFR/ALK) testing was
carried out on tissue procured from the initial right
pleural biopsy. Using this sample with 35 % viable tumor
tissue, the patient was found to be both EGFR wild-type
and ALK-negative by FISH.
Chest computed tomography (CT) scan showed that
the patient had marginal progression of her right pleural
rind along with slow progressive growth of right chest
wall nodule. She also received palliative radiation to her
right chest nodule at this time. In year six, a re-biopsy
was carried out on the chest wall skin, and the results
indicated the presence of a well differentiated adenocar-
cinoma, with mucinous features. Immunohistochemistry
stains were positive for nuclear thyroid transcription
factor-1 and negative for estrogen receptor and proges-
terone receptor, which were consistent with a lung
primary tumor. The tissue obtained was analyzed by
NGS to identify potential actionable mutations. NGS
testing results (Foundation Medicine, Inc., MA) indi-
cated that the tumor was ALK-rearrangement positive
for EIF2AK3-ALK fusion, and the patient received crizo-
tinib treatment for 19 months. The patient responded
well to crizotinib in the first 12 months of treatment
(Fig. 1), with significant interval decrease in the pleural
Fig. 1 Chest CT Scans of Patient on Crizotinib Treatment. a Chest/Upper Abdomen CT Scan Prior to Crizotinib Treatment. b Chest CT Scan
Post-Crizotinib Treatment
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based tumor, mediastinal lymphadenopathy, and sub-
cutaneous metastatic deposits. Continued decreases in
the size of nodules associated with the right pleural-based
tumor, mediastinal lymphadenopathy and subcutaneous
metastatic deposits was seen, followed by stable disease
until 16 months into treatment, when CT showed disease
progression. This manifested as an increase in right dia-
phragmatic pleural-based masses, an increase in right lat-
eral chest wall tumor, and an increase in subcarinal
lymphadenopathy (from prior study). 18 months after the
start of crizotinib treatment, another CT scan showed a
significant response (this was the last CT scan while on
crizotinib treatment), with significant interval decrease in
size of diaphragmatic pleural-based masses and minimal
interval decrease in pleural thickening as described above.
Despite the patient’s overall pronounced response to cri-
zotinib, the treatment was eventually discontinued due to
disease progression and gastrointestinal adverse events of
Grade 3 nausea and vomiting.
Treatment with orally administered ceritinib at a start-
ing dose of 450 mg/day was initiated two months after
crizotinib treatment ended. This ceritinib dose was ad-
ministered with food; meals were generally relatively
bland and small in size (taken three times a day), and
red meat and spice-free. Ceritinib treatment is being well
tolerated, and no gastrointestinal adverse events (nausea,
vomiting, or related bowel problems) have been reported
to date. Proactive treatment regimens have been re-
ported as effective in the management of gastrointestinal
AEs in patients taking ceritinib [15], but regimens of this
type were not required for this patient, who was treated
with ceritinib 450 mg/day with food, and are not cur-
rently considered necessary for her future treatment.
Overall, the patient has reported suffering from minimal
side effects with the exception of some bloating and
rhinorrhea. The patient has also shown a good response
to ceritinib, as demonstrated by CT scans (Fig. 2), and
treatment is currently ongoing. There was no central
nervous system (CNS) involvement.
Conclusions
In this case study, an excellent response to sequential ALK
inhibitor treatment was achieved following re-biopsy in a
patient previously shown to be ALK-negative. It is not
known how common ALK-rearrangements are after treat-
ment with standard chemotherapy or radiotherapy. As data
matures from various trials and clinical experience, further
tumor heterogeneity will be discerned. It is indeed possible
that ALK-rearrangement may be selected for over time. In
this patient, NGS testing revealed ALK-rearranged adeno-
carcinoma, which had not been previously detected by
FISH. After responding to crizotinib treatment, the patient
eventually discontinued the drug due to progressive disease
and gastrointestinal adverse events, and therapy was
switched to second-line ceritinib. The patient responded to
treatment with ceritinib 450 mg/day, taken with food,
without suffering from gastrointestinal adverse events that
are commonly experienced by patients taking the recom-
mended fasting dose of ceritinib of 750 mg/day [13].
Figure 3 summarizes the patient’s oncologic history as a
timeline.
This case study validates the importance of broad
diagnostic testing for actionable mutations in lung can-
cer patients who have progressed on first-line therapy,
including in those who may have already been tested
and found to be negative for oncogenic driver mutations.
For instance, re-biopsy may often provide specimens of
superior quality for molecular testing if original tumor
biopsy samples were heterogeneous in nature. Mutations
not previously detected may also have arisen during
Fig. 2 Chest CT Scans of Patient on Ceritinib Tratment. a Chest CT Scan Prior to Ceritinib Treatment. b Chest/Upper Abdomen CT Scan Post
Ceritinib Treatment
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treatment. Targeted treatment options are available for
those patients where actionable mutations are revealed,
and as in this case, crizotinib provides responses in
many patients found to be ALK-rearrangement positive.
However, crizotinib treatment may need to be discontin-
ued due to progression through drug resistance caused
by either secondary kinase mutations or alternative gen-
etic driver mutations. As an increasing number of ALK
inhibitors are approved for the treatment of patients
with lung cancer, such as crizotinib, ceritinib, and alecti-
nib, the selection of sequential treatments will need to
be based not only on patient’s resistance mutation pro-
files but also on consideration of potential tolerability to
subsequent treatment options.
This study demonstrates the safety, tolerability and ef-
ficacy of second-line ceritinib treatment, when adminis-
tered with food at a lower than recommended dose of
450 mg/day, in a patient with previously treated lung
adenocarcinoma who had discontinued crizotinib due to
disease progression and gastrointestinal adverse events.
Sequentially administered ceritinib at this lower dose is
being well tolerated in this responding patient, with no
gastrointestinal intolerance, and she remains on ceritinib
therapy to date. As recent data has become available
from the J-ALEX study (ASCO, 2016) [16], it may very
well be that alectinib will be one of the first line choices
for ALK positive patients. As well, there are ongoing
studies on Ceritinib in comparison to crizotinib, and
these results are awaited. It is an exciting time for our
patients with ALK positive tumors with a number of op-
tions. How we determine the sequence of therapy is still
under investigation. Ceritinib, discussed here, certainly
has dramatic activity against ALK positive lung cancer.
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